ClinicalTrials.gg
CompletedNCT01104779Updated Nov 14, 2018Results posted

Safety and Efficacy of Cariprazine in Schizophrenia

A Phase 3 interventional study of Cariprazine and Placebo in Schizophrenia, sponsored by Forest Laboratories. Completed at 41 sites in 4 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-11-14.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
446
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.

Enrollment
7th of 23
446 · median 129
Started
2010
with 2 others
Phase 3
8 of 23
1 open now
Registered
7th of 23
by date
Lead sponsor
8 of 23
Forest Laboratories

Among the 23 studies testing cariprazine in Schizophrenia, this one is the 7th largest by enrollment, is one of 3 that started in 2010, is one of 8 in phase 3, and was the 7th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cariprazine

cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cariprazine in Schizophrenia, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.

03

Conditions studied

  • Schizophrenia

Keywords

  • Schizophrenia
  • Acute Schizophrenia
  • Psychotropic Drugs
  • Antipsychotic Agents
  • Mental Disorders
  • Dopamine Agents
  • Central Nervous System Agents
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have provided prior to any study specific procedures
  • Patients currently meeting the , Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia (paranoid type, disorganized type, catatonic type or undifferentiated type), as confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID)
  • Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCIPANSS) total score ≥ 80 and ≤ 120
  • Diagnosis of schizophrenia for a minimum of 1 year before Visit 1
  • Patients with normal physical examination, laboratory, vital signs,and/ or (ECG)

Exclusion criteria

Exclusion Criteria:

  • Patients with a diagnosis of Schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder
  • Patients in their first episode of psychosis
  • Pregnant, breast-feeding, and/or planning to become pregnant and/or breastfeed during the study
  • Pervasive developmental disorder, mental retardation, delirium, dementia, amnestic and other cognitive disorders
  • Known or suspected borderline or antisocial personality disorder or other DSM-IV-TR axis II disorder of sufficient severity to interfere with participation in this study
  • Substance abuse or dependence within the prior 3 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
446 participants (actual)

Study arms

  • Experimental
    Cariprazine (3-6 mg/day)

    Cariprazine once daily fixed-flexible low dose

    Drug: Cariprazine

  • Experimental
    Cariprazine (6-9 mg/day)

    Cariprazine once daily fixed-flexible high dose

    Drug: Cariprazine

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.

    Also known as: RGH-188

  • DrugPlacebo

    Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.

06

What researchers measure

Primary outcomes

  1. Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score

    The Positive and Negative Syndrome Scale is a 30-item rating scale specifically developed to asses both the positive and negative symptom syndromes of patients with schizophrenia. The PANSS total score is rated based on a structured clinical interview with the patient and supporting clinical information obtained from family, hospital staff, or other reliable informants. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point (1 to 7) scale, with 1 being minimal impact, and 7 being highest impact. The cumulative score ranges from 30 to 210. A negative change score indicates improvement.

    Time frame: Baseline to Week 6

Secondary outcomes

  1. Measurement of Schizophrenia Symptoms: Change From Baseline in Clinical Global Impression-Severity (CGI-S)

    The Clinical Global Impressions-Severity scale is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of illness in other participants the physician has observed. The participant is rated on a scale from 1 to 7 with 1 indicating a "normal state" and 7 indicating "among the most extremely ill participants." A higher score indicates greater illness. A negative change score indicates improvement.

    Time frame: Baseline to Week 6

07

Results

Posted Nov 14, 2018

Participant flow

Participant flow — Overall Study
MilestonePlaceboCariprazine (3-6 mg/Day)Cariprazine (6-9 mg/Day)
Started147151148
Completed889686
Not completed595562
Withdrew: Protocol violation122
Withdrew: Lack of efficacy261213
Withdrew: Adverse event131413
Withdrew: Did not meet inc/exc criteria111
Withdrew: Other reasons010
Withdrew: Lost to follow-up201
Withdrew: Withdrawal by subject162532

Outcome measures

PrimaryMeasurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score

The Positive and Negative Syndrome Scale is a 30-item rating scale specifically developed to asses both the positive and negative symptom syndromes of patients with schizophrenia. The PANSS total score is rated based on a structured clinical interview with the patient and supporting clinical information obtained from family, hospital staff, or other reliable informants. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point (1 to 7) scale, with 1 being minimal impact, and 7 being highest impact. The cumulative score ranges from 30 to 210. A negative change score indicates improvement.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · Units on a Scale
Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score
Units on a ScalePlaceboCariprazine (3-6 mg/Day)Cariprazine (6-9 mg/Day)
Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score-16.0 ± 1.6-22.8 ± 1.6-25.9 ± 1.7
Statistical analysis
  • Placebo vs Cariprazine (3-6 mg/Day) · ANCOVA · p = 0.0029 · Mean difference (final values): -6.8 · 95% CI -11.3 to -2.4Cariprazine 3-6 mg/day vs Placebo
  • Placebo vs Cariprazine (6-9 mg/Day) · ANCOVA · p = <0.0001 · Mean difference (final values): -9.9 · 95% CI -14.5 to -5.3Cariprazine 6-9 mg/day vs Placebo
SecondaryMeasurement of Schizophrenia Symptoms: Change From Baseline in Clinical Global Impression-Severity (CGI-S)

The Clinical Global Impressions-Severity scale is a clinician-rated scale that measures the overall severity of a participant's illness in comparison with the severity of illness in other participants the physician has observed. The participant is rated on a scale from 1 to 7 with 1 indicating a "normal state" and 7 indicating "among the most extremely ill participants." A higher score indicates greater illness. A negative change score indicates improvement.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Measurement of Schizophrenia Symptoms: Change From Baseline in Clinical Global Impression-Severity (CGI-S)
units on a scalePlaceboCariprazine (3-6 mg/Day)Cariprazine (6-9 mg/Day)
Measurement of Schizophrenia Symptoms: Change From Baseline in Clinical Global Impression-Severity (CGI-S)-1.0 ± 0.1-1.4 ± 0.1-1.6 ± 0.1
Statistical analysis
  • Placebo vs Cariprazine (3-6 mg/Day) · ANCOVA · p = 0.0115 · Mean difference (final values): -0.3 · 95% CI -0.6 to -0.1Cariprazine 3-6 mg/day vs Placebo
  • Placebo vs Cariprazine (6-9 mg/Day) · ANCOVA · p = <0.0001 · Mean difference (final values): -0.5 · 95% CI -0.8 to -0.3Cariprazine 6-9 mg/day vs Placebo

Adverse events

Collected over Adverse Events were collected for 8 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/147 (0%)13/161 (8.1%)54/147 (36.7%)
Cariprazine (3-6 mg/Day)0/151 (0%)9/167 (5.4%)84/151 (55.6%)
Cariprazine (6-9 mg/Day)0/148 (0%)4/169 (2.4%)86/148 (58.1%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPlaceboCariprazine (3-6 mg/Day)Cariprazine (6-9 mg/Day)
SchizophreniaPsychiatric disorders6/1612/1670/169
Psychotic disorderPsychiatric disorders2/1614/1671/169
Psychomotor hyperactivityNervous system disorders3/1613/1670/169
HyponatraemiaMetabolism and nutrition disorders1/1611/1670/169
AnxietyPsychiatric disorders1/1610/1670/169
Polydipsia psychogenicPsychiatric disorders1/1610/1670/169
Schizophrenia, paranoid typePsychiatric disorders1/1610/1670/169
Suicidal ideationPsychiatric disorders1/1610/1670/169
Angina pectorisCardiac disorders0/1610/1671/169
Blood pressure increasedInvestigations0/1610/1671/169
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboCariprazine (3-6 mg/Day)Cariprazine (6-9 mg/Day)
AkathisiaNervous system disorders5/14724/15125/148
HeadacheNervous system disorders19/14714/15124/148
InsomniaPsychiatric disorders16/14710/15116/148
Extrapyramidal disorderNervous system disorders4/1478/15115/148
RestlessnessPsychiatric disorders7/14710/15115/148
NauseaGastrointestinal disorders7/1477/15114/148
ConstipationGastrointestinal disorders5/14714/15110/148
TremorNervous system disorders3/14712/1518/148
DyspepsiaGastrointestinal disorders6/1473/15110/148
VomitingGastrointestinal disorders4/1478/1518/148

Baseline characteristics

The randomized population is also the safety population.

Age, Continuous
Age, Continuous(Years)PlaceboCariprazine (3-6 mg/Day)Cariprazine (6-9 mg/Day)Total
Mean36.7 ± 11.336.6 ± 10.535.5 ± 9.336.3 ± 10.4
Sex/Gender, Customized
Sex/Gender, Customized(Participants)PlaceboCariprazine (3-6 mg/Day)Cariprazine (6-9 mg/Day)Total
Male110118113341
Female373335105
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboCariprazine (3-6 mg/Day)Cariprazine (6-9 mg/Day)Total
Hispanic or Latino23242774
Not Hispanic or Latino124127121372
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboCariprazine (3-6 mg/Day)Cariprazine (6-9 mg/Day)Total
White26283084
Black or African-American515653160
Asian565656168
American Indian or Alaska Native1113
Native Hawaiian or Other Pacific Islander1023
Other1210628
08

Study locations

41 sites
  • Forest Investigative Site 48
    Costa Mesa, California 92626, United States
  • Forest Investigative Site 50
    Long Beach, California 90813, United States
  • Forest Investigative Site 42
    Paramount, California 90723, United States
  • Forest Investigative Site 054
    San Diego, California 92102, United States
  • Forest Investigative Site 41
    Kissimmee, Florida 34741, United States
  • Forest Investigative Site 055
    Atlanta, Georgia 30308, United States
  • Forest Investigative Site 44
    Rockville, Maryland 20850, United States
  • Forest Investigative Site 45
    Saint Louis, Missouri 63118, United States
  • Forest Investigative Site 52
    Las Vegas, Nevada 89102, United States
  • Forest Investigative Site 40
    Cedarhurst, New York 11516, United States
  • Forest Investigative Site 46
    Cincinnati, Ohio 45219, United States
  • Forest Investigative Site 47
    Philadelphia, Pennsylvania 19139, United States
  • Forest Investigative 49
    Memphis, Tennessee 38119, United States
  • Forest Investigative Site 51
    Houston, Texas 77021, United States
  • Forest Investigative Site 43
    Irving, Texas 75062, United States
  • Forest Investigative Site 601
    Bello, Antioquia 051053, Colombia
  • Forest Investigative Site 604
    Pereira, Risaralda 660003, Colombia
  • Forest Investigative Site 602
    Bogota, 110121, Colombia
  • Forest Investigative Site 605
    Bogota, 111166, Colombia
  • Forest Investigative Site 505
    Vijayawada, Andhra Pradesh 520002, India
  • Forest Investigative Site 514
    Visakhapatnam, Andhra Pradesh 530017, India
  • Forest Investigative Site 503
    Ahmedabad, Gujarat 380006, India
  • Forest Investigative Site 519
    Ahmedabad, Gujarat 380006, India
  • Forest Investigative Site 501
    Ahmedabad, Gujarat 380013, India
  • Forest Investigative Site 508
    Ahmedabad, Gujarat 380015, India
  • Forest Investigative Site 504
    Bangalore, Karna 560010, India
  • Forest Investigative Site 517
    Mangalore, Karna 575001, India
  • Forest Investigative Site 515
    Mangalore, Karna 575018, India
  • Forest Investigative Site 516
    Mysore, Karna 570015, India
  • Forest Investigative Site 500
    Aurangabad, Mahara 431005, India
  • Forest Investigative Site 510
    Mumbai, Mahara 400026, India
  • Forest Investigative Site 513
    Nashik, Mahara 422101, India
  • Forest Investigative Site 511
    Pune, Mahara 411001, India
  • Forest Investigative Site 502
    Pune, Mahara 411030, India
  • Forest Investigative Site 509
    Rajkot, Rajastan 360002, India
  • Forest Investigative Site 507
    Kanpur, Uttar Pradesh 208005, India
  • Forest Investigative Site 518
    Lucknow, Uttar Pradesh 226006, India
  • Forest Investigative Site 506
    Varanasi, Uttar Pradesh 201010, India
  • Forest Investigative Site 704
    Johannesburg, Gauteng 2198, South Africa
  • Forest Investigative Site 703
    Cape Town, W Cape 7530, South Africa
  • Forest Investigative Site 706
    Cape Town, W Cape 7535, South Africa
09

References and documents

Publications

  • Laszlovszky I, Barabassy A, Nemeth G. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety. Adv Ther. 2021 Jul;38(7):3652-3673. doi: 10.1007/s12325-021-01797-5. Epub 2021 Jun 6. PubMed 34091867 ↗
  • Barabassy A, Sebe B, Acsai K, Laszlovszky I, Szatmari B, Earley WR, Nemeth G. Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies. Neuropsychiatr Dis Treat. 2021 Apr 7;17:957-970. doi: 10.2147/NDT.S301225. eCollection 2021. Erratum In: Neuropsychiatr Dis Treat. 2021 May 17;17:1481. doi: 10.2147/NDT.S316858. PubMed 33854317 ↗
  • Marder S, Fleischhacker WW, Earley W, Lu K, Zhong Y, Nemeth G, Laszlovszky I, Szalai E, Durgam S. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies. Eur Neuropsychopharmacol. 2019 Jan;29(1):127-136. doi: 10.1016/j.euroneuro.2018.10.008. Epub 2018 Nov 20. PubMed 30470662 ↗
  • Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane JM. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2017 Nov;32(6):319-328. doi: 10.1097/YIC.0000000000000187. PubMed 28692485 ↗
  • Cutler AJ, Durgam S, Wang Y, Migliore R, Lu K, Laszlovszky I, Nemeth G. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr. 2018 Feb;23(1):39-50. doi: 10.1017/S1092852917000220. Epub 2017 May 8. PubMed 28478771 ↗
  • Citrome L, Durgam S, Lu K, Ferguson P, Laszlovszky I. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. J Clin Psychiatry. 2016 Jan;77(1):109-15. doi: 10.4088/JCP.15m10192. PubMed 26845266 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2010 to primary completion in Dec 2011, 19 months.

Results were first posted in Nov 2018, 6 years 10 months after primary completion. A results delay was requested in Dec 2012.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 19 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2010
First posted
Apr 15, 2010
StartActual
Apr 27, 2010
Primary completionActual
Dec 15, 2011
CompletionActual
Dec 15, 2011
Results delay requested
Dec 6, 2012
Results first posted
Nov 14, 2018
Last update
Nov 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01104779
Collaborators
Gedeon Richter Ltd.
Responsible party
Sponsor
First posted
Apr 15, 2010
Start date
Apr 27, 2010
Primary completion
Dec 15, 2011
Completion
Dec 15, 2011
Results posted
Nov 14, 2018
Last update
Nov 14, 2018

Study contacts

Raffaele Migliore, MA
study director · Forest Laboratories

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion